Phase I/II Study of Combination of Sorafenib, Vorinostat, and Bortezomib for the Treatment of Acute Myeloid Leukemia With Complex- or Poor-risk (Monosomy 5/7) Cytogenetics or FLT3-ITD Positive Genotype
Clinical trial NCT01534260 · COMPLETED
Trial details
- NCT number
- NCT01534260
- Sponsor
- Hamid Sayar
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2012-02-10
- Primary completion
- 2016-08-29
- Enrollment
- 37
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.